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Background: Niacin supplementation improves dyslipidemia and lowers serum
phosphorus levels in patients with chronic kidney disease (CKD). We evaluated
whether low-dose niacin supplementation can improve dyslipidemia, lower serum
phosphorus levels, and be administered with a low frequency of adverse effects in
patients with CKD.
Methods: We retrospectively analyzed the clinical records of patients with CKD
who had taken niacin from January 2009 to June 2011. We excluded patients with
CKD stage 1 and 5. We then enrolled 31 patients with CKD who had taken niacin at
a ﬁxed dose of 500 mg/day for 6 months. We also randomly selected 30 patients
with CKD who had been taking statin for 9 months as a control group.
Results: Among the 34 patients with CKD who were prescribed niacin, ﬁve (14%)
complained of adverse effects, and three (8%) discontinued niacin. The proportion
of patients in the niacin group who had been taking a statin or omega-3 fatty acids
was 67.7% and 48.8%, respectively. In the niacin group, high-density lipoprotein
cholesterol level was signiﬁcantly increased and triglyceride level was signiﬁcantly
decreased at 12 and 24 weeks compared with baseline levels (Po0.05). In the
niacin group, phosphorous level (Po0.05) was signiﬁcantly decreased, and
glomerular ﬁltration rate (GFR) was signiﬁcantly increased (Po0.05) at 24 weeks
compared with baseline values.
Conclusion: Low-dose niacin had a low frequency of adverse effects and also
improved dyslipidemia, lowered serum phosphorus level, and increased GFR in
patients with CKD. Further studies are needed to evaluate the long-term effects of
low-dose niacin for renal progression of CKD.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).rean Society of Nephrology. P
ses/by-nc-nd/4.0/).
ernal Medicine, Dong-A
Busan 602-715, Korea.Introduction
Niacin is a water-soluble vitamin, which is critical for
cellular metabolism [1]. As a broad-spectrum drug that can
affect lipid levels, niacin reduces levels of total cholesterol,
triglyceride, and low-density lipoprotein (LDL) cholesterol,
while increasing high-density lipoprotein (HDL) cholesterol
levels when administered at a dose of 1–3 g/day [2–4]. Niacinublished by Elsevier. This is an open access article under the CC BY-NC-
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kidney disease (CKD), dyslipidemia, and diabetes mellitus
[4,5]. Furthermore, niacin plays a key role in cardiovascular
diseases and cardiovascular-related mortality by modifying
both dyslipidemia and phosphorus levels [6–9].
Despite these positive roles of niacin, physicians hesitate to
prescribe niacin because of its various adverse effects such as hot
ﬂushing, liver function test disruption, and thrombocytopenia.
Although some of these adverse effects are slight and easily
controlled by symptomatic care, some effects such as hot ﬂushing
necessitate cessation of niacin administration [3,4]. Therefore, it is
necessary to judge whether the beneﬁts of low-dose niacin
administration outweigh its adverse effects.
In this study, we retrospectively analyzed whether low-dose
niacin supplementation improves dyslipidemia and lowers
serum phosphorus levels with less adverse effects in patients
with CKD.Methods
Study population
We retrospectively analyzed the clinical records of 45 patients
with CKD who had maintained dosing with an extended release
formulation of ﬁxed low-dose (500 mg) niacin (Niaspanor;
Merck KGaA, Darmstadt, Germany) at Dong-A University Hospi-
tal between January 2009 and June 2011. We excluded eight
patients with CKD stage 1 and 5. We also excluded three patientsTable 1. Baseline characteristics of the study populations
Control group (n¼3
Age (y) 59.3717.8
Male gender (%) 19 (61.3)
Smoking history (%) 9 (30.0)
Body mass index (kg/m2) 24.673.8
Systolic blood pressure (mmHg) 129.4725.0
Diastolic blood pressure (mmHg) 77.1715.4
Diabetes (%) 13 (43.3)
Coronary artery disease (%) 7 (23.3)
Peripheral artery disease (%) 9 (30.0)
Cerebrovascular disease (%) 9 (30.0)
Chronic kidney disease
Stage 2 (%) 11 (36.7)
Stage 3 (%) 13 (43.3)
Stage 4 (%) 6 (20.0)
Medications
Calcium channel blocker (%) 16 (53.3)
Beta-blocker (%) 10 (16.4)
Furosemide (%) 11 (36.7)
Spironolactone (%) 3 (10)
ACEI (%) 14 (46.7)
ARB (%) 19 (63.3)
Digoxin (%) 3 (10)
Aspirin (%) 8 (26.7)
Clopidogrel (%) 14 (46.7)
Allopurinol (%) 2 (6.7)
Omega-3 fatty acid (%) 11 (36.7)
Statin (%) 30 (100)
Fluvastatin (%) 12 (40)
Pravastatin (%) 9 (30)
Atorvastatin (%) 6 (20)
Rosuvastatin (%) 3 (10)
Hypertension medication count 2.571.1
Data are expressed as mean7SD.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptorwho had additional prescriptions such as 3-hydroxy-3-methyl-
glutaryl-coenzyme A reductase inhibitors (statin) or omega-3
fatty acid (FA) during the investigational period. Among the 34
enrolled patients, we additionally excluded three patients who
had quit taking niacin due to adverse drug reactions. Finally, we
enrolled 31 patients with CKD who had taken niacin at a ﬁxed
dose of 500 mg/day for 6 months and analyzed 34 patients for
adverse effects. Niacin was prescribed for reducing triglyceride
and increasing HDL levels in the enrolled 31 patients with CKD.
There were no patients who were hospitalized during the
investigational period in the niacin group. We randomly selected
60 patients with CKD who had been taking a statin for 9 months
or more as a control group. We deﬁned baseline point of control
group as the point after using statin for 3 months because the
control group should be having controlling levels of cholesterol
similar to the niacin group. We excluded 14 patients with CKD
stage 1 and 5. We also excluded ﬁve patients whose baseline
HDL level was 440 mg/dL in men, and 450mg/dL in women
so as to match with the niacin group. We excluded three more
patients who were hospitalized and seven who had prescription
changes such as addition of omega-3 FA during the investiga-
tional period. Finally, we enrolled 30 patients with CKD who had
been taking a statin for 9 months or more as the control group.
Laboratory tests and clinical ﬁndings
We deﬁned baseline as the ﬁrst prescription point of niacin
in the niacin group and as the point after receiving a 3-month
statin prescription in the control group. The following0) Niacin group (n¼31) P
55.8714.8 0.245
12 (38.7) 0.074
4 (12.9) 0.127
23.972.8 0.564
124.8720.8 0.613
77.3712.0 0.760
10 (32.3) 0.434
7 (22.6) 1.000
5 (16.1) 0.235
5 (16.1) 0.286
12 (38.7) –
13 (41.9) –
6 (19.4) –
12 (38.7) 0.309
10 (16.4) 1.000
12 (38.7) 1.000
4 (12.9) 1.000
5 (16.1) 0.013
19 (61.3) 1.000
4 (12.9) 1.000
8 (25.8) 1.000
8 (25.8) 0.114
6 (19.4) 0.255
15 (48.4) 0.440
21 (67.7) 0.001
9 (42) –
7 (33) –
4 (19) –
1 (6) –
2.071.4 0.198
blocker.
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age, gender, smoking history, body mass index, and underlying
comorbidities including diabetes mellitus, coronary artery dis-
ease, peripheral arterial disease, and cerebrovascular disease.
We deﬁned coronary artery disease as those with previous
diagnosis by coronary angiography, echocardiography, electro-
cardiography changes, elevated levels of troponin I, or myocar-
dial single-photon emission computed tomography scans. We
deﬁned cerebrovascular disease as those with previous ischemic
stroke and brain hemorrhages diagnosed by clinical manifesta-
tion and magnetic resonance imaging. We deﬁned peripheral
arterial disease as those with previous amputation of extremi-
ties or diagnosis by Doppler ultrasonography of extremities.
We investigated systolic and diastolic blood pressures at
baseline and after 12 and 24 weeks. We analyzed the follow-
ing laboratory ﬁndings at the same intervals: hemoglobin,
platelet count, calcium, phosphorus, blood urea nitrogen,
creatinine, glomerular ﬁltration rate (GFR), albumin, uric acid,
aspartate aminotransferases, alanine aminotransferase, alka-
line phosphatase (ALP), total cholesterol, triglyceride, HDL, LDL,
C-reactive protein, HbA1c, random urine protein-to-creatinine
ratio, and random urine microalbumin-to-creatinine ratio. We
could not investigate serum parathyroid hormone, urine
sodium, and urine phosphorus levels because these data were
missing in most of the enrolled patients. GFR was estimated
using the modiﬁcation of diet in a renal disease study formula.
The patients who were taking calcium-channel blockers, beta
blockers, nitrates, furosemide, spironolactone, digoxin, low-dose
aspirin, clopidogrel, allopurinol, omega-3 FA (Omacor; Pronova,
Sandefjord, Norway), statins, angiotensin-converting enzyme
inhibitors (ACEIs), or angiotensin II receptor blockers (ARBs)
during the follow-up period were noted.
Statistical analysis
Descriptive statistics that used means and standard devia-
tions are presented as continuous variables, with theTable 2. Baseline laboratory ﬁndings of study populations
Control group (
Hemoglobin (g/dL) 12.972.2
Platelet count (103/mL) 216.0765.2
Calcium (mg/dL) 9.070.4
Phosphorus (mg/dL) 3.670.5
Calcium–phosphorus product (mg2/dL2) 32.374.8
Blood urea nitrogen (mg/dL) 24.3711.0
Creatinine (mg/dL) 1.670.7
GFR (mL/min/1.73m2) 51.0719.6
Albumin (g/dL) 4.270.3
Uric acid (mg/dL) 7.071.6
SGOT (IU/L) 22.378.0
SGPT (IU/L) 23.0711.5
Alkaline phosphatase (IU/L) 241.4799.2
Total cholesterol (mg/dL) 182.4748.2
Triglyceride (mg/dL) 239.47192.1
HDL (mg/dL) 39.377.4
LDL (mg/dL) 98.5733.0
C-reactive protein (mg/dL) 0.170.1
HbA1c (%) 6.872.1
RU P/C ratio (g/g) 1.370.4
RU A/C ratio (mg/g) 209.4770.5
Data are expressed as mean7SD, except random urine P/C ratio and rando
GFR, MDRD-estimated glomerular ﬁltration rate; HDL, high-density lipop
modiﬁcation of diet in a renal disease study; RU A/C ratio, random urine
creatinine ratio; SGOT, serum glutamic oxaloacetic transaminase (amin
aminotransferase).exceptions of the urine albumin-to-creatinine ratio and urine
protein-to-creatinine ratio, which used means and standard
error. The nonparametric Mann–Whitney U test was used to
compare baseline data between the control and the niacin
groups. The Fisher exact test was used to compare categorical
data between the two groups. The nonparametric Wilcoxon
rank-sum test was applied to compare baseline data with 12-
and 24-week data. A P value r0.05 was considered to be
statistically signiﬁcant for all the tests. Statistical analyses
were performed using SPSS 19.0 (SPSS Inc., Chicago, IL, USA).Results
Baseline characteristics of study populations
The baseline characteristics were similar between the two
groups (Tables 1 and 2). The mean age, lipid proﬁles, phos-
phorous levels, creatinine, and GFR were not signiﬁcantly
different between the niacin group and the control group.
In the niacin group, the percentage of patients already treated
with a statin, omega-3 FA, both niacin and omega-3 FA, and
neither of the medications was 67.7%, 48.8%, 38.7%, and 19.6%,
respectively. The percentage of patient taking omega-3 FA was
36.7% in the control group. The percentage of patient taking ACEI
in the niacin group was signiﬁcantly lower than that in the
control group, but administration of ARB medication was similar
between the two groups. The percentage of patients taking both
an ACEI and an ARB in the niacin group was signiﬁcantly lower
than that in the control group (6.5% vs. 26.7%, P¼0.043).
Adverse effects of niacin
Among the 34 patients with CKD who were prescribed niacin,
ﬁve patients (14%) complained of adverse effects of niacin and
three patients (8%) discontinued niacin. Three patients (8%)
experienced ﬂushing, one had ﬂushing with itching, and anothern¼30) Niacin group (n¼31) P
12.971.8 0.729
231.5756.9 0.264
9.170.5 0.439
3.770.6 0.406
33.875.8 0.341
22.0711.1 0.348
1.570.7 0.405
53.4722.0 0.692
4.370.3 0.174
6.872.0 0.862
21.578.9 0.366
20.9711.4 0.347
254.9771.2 0.306
178.5734.2 0.851
221.17112.9 0.484
37.078.2 0.079
93.5726.7 0.479
0.370.6 0.603
7.071.7 0.593
1.1 70.5 0.832
227.1754.9 0.872
m urine A/C ratio, which were expressed as mean7SE.
rotein cholesterol; LDL, low-density lipoprotein cholesterol; MDRD,
albumin-to-creatinine ratio; RU P/C ratio, random urine protein-to-
otransferases); SGPT, serum glutamic pyruvic transaminase (alanine
Table 3. Changes in biochemical data by niacin supplementation
Control group (baseline) Control group (24 wks) Niacin group (baseline) Niacin group (24 wks)
Systolic BP (mmHg) 129.472 5.0 124.6715.2 124.8720.8 124.5718.0
Diastolic BP (mmHg) 77.1715.4 77.6712.4 77.3712.0 72.3717.8
Hemoglobin (g/dL) 12.972.2 12.772.2 12.971.8 12.871.8
Platelet count (103/mL) 216.0765.2 219.0760.9 231.5756.9 221.0762.6n
Calcium (mg/dL) 9.070.4 8.870.4n 9.170.5 9.070.4
Phosphorus (mg/dL) 3.670.5 3.670.6 3.770.6 3.270.7n
Calcium–phosphorus product (mg2/dL2) 32.374.8 32.175.3 33.875.8 28.976.0n
Blood urea nitrogen (mg/dL) 24.3711.0 24.5711.8 22.0711.1 23.176.5
Creatinine (mg/dL) 1.670.7 2.072.0 1.570.7 1.470.7
GFR (mL/min/1.73 m2) 51.0719.6 52.0722.2 53.4722.0 56.6724.3n
Albumin (g/dL) 4.270.3 4.270.4 4.370.3 4.470.2
Uric acid (mg/dL) 7.071.6 7.471.6 6.872.0 6.471.8n
SGOT (IU/L) 22.378.0 23.178.6 21.578.9 23.5710.7
SGPT (IU/L) 23.0711.5 24.9716.1 20.9711.4 22.7717.4
Alkaline phosphatase (IU/L) 241.4799.2 246.7766.3 254.9771.2 274.4782.2n
Total cholesterol (mg/dL) 182.4748.2 173.1747.9 178.5734.2 162.0728.5
Triglyceride (mg/dL) 239.47192.1 173.07101.9n 221.171 12.9 168.47100.2n
HDL (mg/dL) 39.377.4 43.279.1n 37.078.2 42.678.2n
LDL (mg/dL) 98.5733.0 91.3733.9 93.5726.7 87.2724.7
C-reactive protein (mg/dL) 0.170.1 0.170.1 0.370.6 0.370.5
HbA1c 6.872.1 6.971.5 7.071.7 6.670.8
RU P/C ratio (g/g) 1.370.4 1.470.4 1.170.5 1.270.5
RU A/C ratio (mg/g) 209.4770.5 169.8762.0 227.1754.9 195.5763.3
n Po0.05 (mean values are signiﬁcantly different from baseline).
Data are expressed as mean7SD.
BP, blood pressure; GFR, MDRD-estimated glomerular ﬁltration rate; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein
cholesterol; MDRD, modiﬁcation of diet in a renal disease study; RU A/C ratio, random urine albumin-to-creatinine ratio; RU P/C ratio, random urine
protein-to-creatinine ratio; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase.
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found the side effect tolerable and continued to take niacin
throughout the 24-week period without cessation. The mean
platelet counts were signiﬁcantly decreased at 12 and 24 weeks
in the niacin group, but the counts remained within normal
ranges.
Changes in biochemical data and clinical ﬁndings
There were no changes in statin dose, ACEI, or ARB medica-
tions during the investigational period in either the niacin group
or the control group. There were no signiﬁcant changes in
blood pressure, creatinine, LDL cholesterol, C-reactive protein,
random urine protein-to-creatinine ratio, and random urine
microalbumin-to-creatinine ratio in both groups (Table 3).
HDL cholesterol was signiﬁcantly increased at 12
(P¼0.003) and 24 weeks (Po0.001) compared with baseline
in the niacin group, but HDL cholesterol was signiﬁcantly
increased at only 24 weeks (P¼0.001) compared with base-
line in the control group (Fig. 1A). Triglyceride level was
signiﬁcantly decreased at 12 (P¼0.016) and 24 weeks
(P¼0.001) compared with baseline in the niacin group, but
was signiﬁcantly decreased at only 24 weeks (P¼0.007)
compared with baseline in the control group (Fig. 1B).
Serum phosphorus levels (P¼0.006) and calcium–phosphorus
product (P¼0.001) were signiﬁcantly decreased at 24 weeks
compared with baseline in the niacin group, but there was no
change in serum phosphorus levels (Fig. 1C) and calcium–
phosphorus product at 24 weeks compared with baseline in the
control group. GFR (P¼0.016) was signiﬁcantly increased at 24
weeks compared with baseline in the niacin group, although
serum creatinine was not signiﬁcantly changed in the niacin
group (Fig. 1D). GFR was signiﬁcantly increased (55.4724.5 mL/
min/1.73 m2 vs. 62.8728.3 mL/min/1.73 m2, P¼0.016) and
serum creatinine was signiﬁcantly decreased (1.570.8 mg/dL vs. 1.370.7 mg/dL, P¼0.021) at 24 weeks compared
with baseline in the niacin subgroup without statin medication.
There were no signiﬁcant changes in GFR and serum creatinine
at 24 weeks compared with baseline in the niacin subgroup
taking statin. Uric acid level was signiﬁcantly decreased
(P¼0.033) and ALP level was signiﬁcantly increased (P¼0.019)
at 24 weeks compared with baseline in the niacin group.Discussion
In this study, signiﬁcant changes in HDL, triglyceride, and
phosphorus levels were found by administering low-dose
niacin in patients with CKD. In addition, the frequency and
severity of the adverse effects were lower than in previous
studies, which used routine doses of niacin in patients with
CKD. The prevalence rate of adverse effects was 14% and
compliance rate was 92% for a 6-month period in this study.
Recent studies using niacin showed that a typical starting
dose of niacin was 500 mg or 1 g/day, and the dose was
advanced in phases to reach a given target dose to accom-
modate the drug’s adverse effects [3,4,10,11]. Compliance
rates in these studies were reported to be 57–80% [11–13].
Thrombocytopenia is one of the adverse effects caused by
niacin supplementation. In our study, platelet count was
signiﬁcantly decreased after 12 weeks, but remained in the
normal range. We suspect that only a mild decrease of
platelet count rather than severe thrombocytopenia may be
caused by administration of low-dose niacin. In addition,
there were no speciﬁc adverse effects in 38.7% of patients
who were managed with triple antilipid therapy (statin,
omega-3 FA, and low-dose niacin). Therefore, our study
supports that low-dose niacin (500 mg/day) administered
for control of dyslipidemia is a relatively safe and effective
dose in patients with CKD stage 2-4.
Figure. 1. Changes in the levels of HDL (A), triglyceride (B), phosphorus (C), and GFR (D) after niacin administration. GFR, glomerular ﬁltration
rate; HDL, high-density lipoprotein cholesterol. nPo0.05 (mean values are signiﬁcantly different from baseline in niacin group). yPo0.05 (mean
values are signiﬁcantly different from baseline in control group).
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decreasing triglyceride levels was also noted in this study
by administering the low-dose niacin. It is not clear as to why
a low dose of niacin effectively controls dyslipidemia in
patients with CKD. Results of a previous study showed that
treatment with a low dose of pravastatin showed primary
prevention of cardiovascular disease in a Japanese population
[14]. Therefore, further studies are necessary to conﬁrm the
effect of low-dose niacin in other ethnic populations, such as a
cohort of Western population.
Niacin is now known to inhibit sodium/phosphorous co-
transporters in both renal proximal tubules and intestinal
brush borders [15,16]. Hyperphosphatemia is one of the main
features of CKD-mineral and bone disorder and is linked to
cardiovascular risk as well as bone disease [17]. The hyper-
phosphatemic milieu may promote vascular calciﬁcation
through cellular changes in vascular smooth muscle cells
[18]. Therefore, a low dose of niacin may be helpful not only
for the control of dyslipidemia, but also for the early preven-
tion of hyperphosphatemia in patients with CKD. Meanwhile,
a comparison with baseline revealed increased ALP level after
niacin supplementation in our study. Increased ALP level after
niacin supplementation was also found in animal and human
studies [19,20]. It is unknown which source of ALP was
increased, but the effect may have been a compensatory
response caused by decreased phosphorous levels. In contrast,decreased ALP level after niacin supplementation was shown in
hemodialysis patients with hyperphosphatemia [21,22]. Further
studies will be needed to evaluate the effects of niacin on ALP
according to phosphorous and parathyroid hormone levels.
In this study, GFR was signiﬁcantly improved by niacin
supplementation after 24 weeks in patients with CKD. In
addition, signiﬁcantly decreased level of serum creatinine was
found after 24 weeks in the subgroup treated with niacin and
without statin. Therefore, the renoprotective effect of niacin
was not related with statin co-administration although the
combination of niacin and statin showed cardioprotective
effect in another study [23]. Recently, niacin administration
was reported to improve GFR and kidney function in 5/6
nephrectomized rat model [24]. This study may explain the
improved renal function because niacin improves renal tissue
lipid metabolism, oxidative stress, and inﬂammation. How-
ever, further prospective studies are necessary to conﬁrm the
effect of niacin on the GFR in patients with CKD.
An increase of serum uric acid levels could be regularly
seen during treatment with niacin [3]. However, decreased
serum uric acid levels were found in the niacin group of our
study. We partially explain this result based on the slightly
increased prescription rate for allopurinol and increased GFR
in the niacin group.
Interpretation of the current study in patients with CKD is
limited, because the data were derived from a small sample
Kidney Res Clin Pract 32 (2013) 21–2626size and the study employed a retrospective design. Despite
these limitations, this study is the ﬁrst report showing that
administration of niacin at a dose of 500 mg/day improves
several clinical ﬁndings in patients with CKD.
In conclusion, low-dose niacin (500 mg/day) produced a
low frequency of adverse effects and also improved dyslipi-
demia, lowered serum phosphorus levels, and increased
GFR in patients with CKD. Further studies are necessary to
evaluate the long-term effects of low-dose niacin for renal
progression of CKD.Conﬂict of interest
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